The shares of Editas Medicine, Inc. have increased by more than 55.11% this year alone. The shares recently went down by -7.75% or -$2.12 and now trades at $25.17. The shares of Abraxas Petroleum Corporation (NASDAQ:AXAS), has slumped by -21.01% year to date as of 12/05/2017. The shares currently trade at $2.03 and have been able to report a change of 0.00% over the past one week.
The stock of Editas Medicine, Inc. and Abraxas Petroleum Corporation were two of the most active stocks on Tueday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.
Profitability and Returns
Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. The ROI of EDIT is -54.10% while that of AXAS is -63.30%. These figures suggest that EDIT ventures generate a higher ROI than that of AXAS.
The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, EDIT’s free cash flow per share is a negative -0.49, while that of AXAS is also a negative -0.07.
Liquidity and Financial Risk
The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for EDIT is 10.10 and that of AXAS is 0.50. This implies that it is easier for EDIT to cover its immediate obligations over the next 12 months than AXAS. The debt ratio of EDIT is 0.00 compared to 0.62 for AXAS. AXAS can be able to settle its long-term debts and thus is a lower financial risk than EDIT.
EDIT currently trades at a P/B of 5.85, and a P/S of 93.65 while AXAS trades at a forward P/E of 7.41, a P/B of 3.03, and a P/S of 4.20. This means that looking at the earnings, book values and sales basis, AXAS is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.
Analyst Price Targets and Opinions
The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of EDIT is currently at a -24.21% to its one-year price target of 33.21. Looking at its rival pricing, AXAS is at a -24.54% relative to its price target of 2.69. This figure implies that over the next one year, AXAS is a better investment.
When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), EDIT is given a 2.50 while 1.60 placed for AXAS. This means that analysts are more bullish on the outlook for EDIT stocks.
Insider Activity and Investor Sentiment
Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for EDIT is 5.98 while that of AXAS is just 1.63. This means that analysts are more bullish on the forecast for AXAS stock.
The stock of Editas Medicine, Inc. defeats that of Abraxas Petroleum Corporation when the two are compared, with EDIT taking 5 out of the total factors that were been considered. EDIT happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, EDIT is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for EDIT is better on when it is viewed on short interest.